We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
QDEL

Price
35.87
Stock movement up
+0.85 (2.43%)
Company name
Quidel Corporation
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Medical Devices
Markedsværdi
2.41B
Ent værdi
5.88B
Pris/omsætning
0.86
Pris/bog
0.76
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-26.86%
Efterfølgende P/E
-
Fremtidig P/E
14.64
PEG
-
EPS-vekst
-
1 års afkast
-24.44%
3 års afkast
-32.01%
5 års afkast
-16.49%
10 års afkast
3.42%
Senest opdateret: 2025-03-28

UDBYTTE

QDEL betaler ikke udbytte

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF24.20
Pris til FCF-
Pris til EBITDA4.22
EV i forhold til EBITDA10.30

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning0.86
Pris til egenkapital0.76
EV i forhold til salg2.09

iO Charts is a Seeking Alpha partner

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier67.26M
EPS (TTM)-27.74
FCF pr. aktie (TTM)-1.44

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)2.82B
Bruttofortjeneste (TTM)1.17B
Driftsindkomst (TTM)30.70M
Nettoindkomst (TTM)-1.87B
EPS (TTM)-27.74
EPS (1 år frem)2.45

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)41.68%
Driftsmargin (TTM)1.09%
Fortjenstmargin (TTM)-66.29%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter143.70M
Nettotilgodehavender334.40M
Omsætningsaktiver i alt1.41B
Goodwill770.60M
Immaterielle aktiver2.80B
Ejendomme, anlæg og udstyr0.00
Sum aktiver6.80B
Kreditor247.20M
Kortfristet/nuværende langsigtet gæld2.76B
Summen af kortfristede forpligtelser1.03B
Sum gæld3.61B
Aktionærernes egenkapital3.19B
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)99.70M
Investeringsudgifter (TTM)196.50M
Fri pengestrøm (TTM)-96.80M
Udbetalt udbytte (TTM)26.00M

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-58.57%
Afkast af aktiver-27.45%
Afkast af investeret kapital-51.97%
Kontant afkast af investeret kapital-2.69%

iO Charts is a Seeking Alpha partner

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning34.96
Daglig høj36.04
Daglig lav34.58
Daglig volumen685K
Højeste gennem alle tider301.96
1 års analytiker estimat51.14
Beta0.12
EPS (TTM)-27.74
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation14 May 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
QDELS&P500
Nuværende prisfald fra top notering-88.12%-7.48%
Højeste prisfald-90.08%-56.47%
Højeste efterår dato10 Jul 20249 Mar 2009
Gennemsnitlig fald fra toppen-38.05%-11.07%
Gennemsnitlig tid til nyt højdepunkt49 days12 days
Maks. tid til nyt højdepunkt1304 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
QDEL (Quidel Corporation) company logo
Markedsværdi
2.41B
Markedsværdi kategori
Mid-cap
Beskrivelse
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Personale
7100
Investor relationer
-
SEC-indsendelser
Adm. direktør
Douglas C. Bryant
Land
USA
By
San Diego
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN